Abbott Q3 2026 earnings call: Strong execution fuels balanced growth across the portfolio

CEO Robert Ford offered insights into Abbott's third-quarter performance, innovation milestones and the outlook for future growth

Abbott's third-quarter results are in, and we delivered an acceleration in growth on both the top and bottom lines compared to the first half of the year. Sales grew 7.0% on a comparable basis* (14.5% reported), in line with consensus estimates. Adjusted diluted earnings per share (EPS) increased 9.2% to $1.42 (GAAP diluted EPS was $0.53), in line with consensus estimates. 

Q3 at-a-glance

Abbott Chairman and CEO Robert Ford shared insights on the third-quarter results, outlining our strategy for delivering sustainable growth in the years ahead. Here are some of the key takeaways for investors.

What fueled Nutrition sales growth?

As we previously forecasted, Nutrition returned to positive growth this quarter, delivering a 4.9% (5.1% reported) increase in total sales. Growth was broad-based across all four segments, led by Pediatric Nutrition, where sales grew 8.7% (8.8% reported) overall and 11.0% in the U.S.

"As I mentioned previously, the team has done an exceptional job executing a more balanced growth strategy, achieving a more sustainable mix of volume and price driven growth," Ford said.

Pipeline progress also contributed to the strong performance in Nutrition. In the third quarter, we launched two new products: Ensure® Max Protein 3-in-1 Muscle Support, which includes protein, creatine and calcium beta-hydroxy-beta-methylbutyrate (HMB), and Similac® 360 Total Care® Made With Whole Milk, the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the U.S.

How is Abbott's Volt® Pulsed Field Ablation (PFA) System  driving growth?

Medical Devices sales growth of 7.8% (6.9% reported) was led by 15.5% (15.0% reported) growth in Electrophysiology. Ford said the third-quarter Electrophysiology performance reflects the "early beginning of our growth acceleration phase." In the U.S., Electrophysiology growth exceeded 20% when excluding left atrial appendage (LAA) sales. 

"This strong performance was driven by increasing adoption of our new Volt PFA catheter, with momentum accelerating in September following the transition to full U.S. market release in August," Ford said.

International Electrophysiology sales grew 13.1% (12.2% reported) as we continue to capture market share in Europe, which Ford said is driven by increasing uptake of our new PFA catheters and growth in other categories across the portfolio.

What innovations came out of Abbott's pipeline in Q3 and what's ahead in Q4?

Innovation is a key differentiator for Abbott—and our third-quarter pipeline progress demonstrated that. We received five new product approvals across multiple business segments during the quarter. In addition to Similac® Total Care® Made With Whole Milk, we also received approval for:

  • Libre Duo 10 Day: In August, the FDA approved Abbott's Libre Duo 10 Day, the world's first dual glucose-ketone sensing system, which supports daily diabetes management and helps detect rising ketone levels that can lead to a diabetic ketoacidosis emergency. "This marks the first time that people with diabetes will be able to monitor ketones without the need for traditional blood or urine tests," Ford said. "We expect to launch this new sensor in the U.S. in December."
  • Amulet 360™ LAA Occluder: Abbott received CE Mark for our next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib), and we look forward to bringing this new technology to the U.S. soon.
  • TactiFlex™ Duo Ablation Catheter, Sensor Enabled™: We received earlier-than-expected FDA approval for TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, in September. "This catheter enables physicians to seamlessly switch between using RF and PFA energy during a procedure," Ford said. "Given physicians’ familiarity with the TactiFlex platform, we expect to execute a broad U.S. launch starting in the fourth quarter."
  • SimpleScreen™ CRC: In September, we launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer (CRC) screening test. SimpleScreen™ CRC joins Cologuard™ in our CRC screening portfolio, making Abbott the only company that offers both stool- and blood-based CRC screening options. 

In addition to these pipeline milestones, Abbott continues to position the company for sustainable growth with new innovations still in development. Ford said we expect to begin key trials for four technologies in the fourth quarter: a leadless conduction system pacing device leveraging our Aveir® pacemaker systems, a balloon-expandable transcatheter aortic valve replacement (TAVR) valve, a mitral valve replacement developed following our acquisition of Cephea Valve Technologies, and a wearable continuous lactate monitoring sensor designed to reduce the risk of sepsis.

What is Abbott's full-year 2026 outlook? 

Abbott tightened our previously provided full-year adjusted diluted EPS guidance range to $5.50 to $5.55 (previous range was $5.45 to $5.60), reaffirming the midpoint, which is in line with consensus estimates. We project full-year 2026 comparable sales growth to be approximately 6.0%. 

"Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," Ford said in the earnings release. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

Explore Q3 results

References

* Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, an oncology diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments received by the Structural Heart business under a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

1. On a GAAP basis, third-quarter Abbott sales increased 14.5%. 

2. Third-quarter GAAP diluted EPS was $0.53. 

3. Third-quarter GAAP diluted EPS decreased by 43.6%. 

4. On a GAAP basis, third-quarter Medical Devices sales increased 6.9%, Diagnostics sales increased 46.7%, Nutrition sales increased 5.1%, and Established Pharmaceuticals sales increased 6.8%.

Forward-looking statements 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Important safety information

Volt PFA System

Indications, Safety & Warnings

Rx Only. Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use.

United States: Required Safety Information

Indications for Use: The Volt™ PFA Catheter, Sensor Enabled™ is indicated for the treatment of symptomatic, recurrent, drug-refractory paroxysmal or persistent (episode duration less than one year) atrial fibrillation when used in conjunction with a compatible pulsed field ablation (PFA) generator. The catheter is compatible with the EnSite™ X EP System. Contraindications: The Volt™ PFA Catheter, Sensor Enabled™ is contraindicated for: ▪ Patients who have had a ventriculotomy or atriotomy within the preceding four weeks. ▪ Patients with prosthetic valves as the catheter may damage the prosthesis. ▪ Patients with an active systemic infection as this may increase the risk for cardiac infection. ▪ Patients with a myxoma or an intracardiac thrombus as the catheter could precipitate an embolus. ▪ Patients unable to receive heparin or an acceptable alternative to achieve adequate anti-coagulation. The transseptal approach is contraindicated in a patient with an interatrial baffle or patch because the opening could persist and produce an iatrogenic atrial shunt. The retrograde trans-aortic approach is contraindicated in patients who have had aortic valve replacement. Warnings: Misuse of this device may result in serious complications. Do not alter this device in any way. This device is intended for one time use only; do not reprocess or reuse it. Note the product “Use by” date on the package. Any attempt to resterilize and reuse this system may compromise its integrity. Adverse effects of using nonsterile components may include, but are not limited to:  ▪ Local or systemic infection or reaction ▪ Mechanical damage ▪ Inaccurate functionality. For both patients and laboratory staff, cardiac catheterization procedures present the potential for significant x-ray exposure, which can result in acute radiation injury as well as increased risk for somatic and genetic effects due to the x-ray beam intensity and duration of the fluoroscopic imaging. Carefully consider the use of this device in pregnant women. This device should be used by physicians trained in the techniques of catheter ablation in a fully equipped electrophysiology laboratory. Do not immerse the proximal handle or cable connectors in fluids; electrical performance could be affected. Do not use excessive force to advance or withdraw the catheter when resistance is encountered. Vascular perforation or dissection is an inherent risk of any catheter placement. Careful catheter manipulation must be performed to avoid device component damage, thromboembolism, cerebrovascular accident, cardiac damage, perforation, pericardial effusion, or tamponade. The safety and long-term effects of lesions created by pulse field ablation have not been established. In particular, the long-term effects of lesions in proximity to the specialized conduction system or coronary vasculature are unknown. The safety and effectiveness of the device has not been established in pregnant women or pre-pubescent children. Careful consideration must therefore be given for the use of the device in pregnant women or prepubescent children. Concurrent use of non-linear catheters within the atrial chamber may increase the risk of entanglement. Catheter entanglement with other device is a possible complication of electrophysiology procedures. To unentangle the Volt™ PFA Catheter, Sensor Enabled™, deflate the balloon and manipulate the opposing catheter to the center of the basket electrodes. Follow any relevant entanglement procedures from the opposing device. Aspiration during catheter introduction or withdrawal is recommended to limit the potential for air ingress into the patient. During catheter preparation, rinsing or submerging the basket in saline reduces the potential for blood coagulation. During catheter preparation, shifting the straightener over the basket removes any residual air remaining in the folds of the balloon and reduces the potential for air embolism. Use of a syringe larger than 12 mL for balloon inflation increases the risk of overinflation. This can result in detachment of the spline electrodes at the distal coupler. Pacemakers and implantable cardioverter/defibrillators can be affected adversely by PFA signals. It is important to:  ▪ Have temporary external sources of pacing and defibrillation available during ablation. ▪ Deactivate ICDs because they can discharge and injure the patient or even damage the ICDs during the ablation procedure. ▪ Exercise extreme caution while ablating near atrial or ventricular permanent pacing leads. ▪ Perform complete pacing system analysis on all patients after ablation. Precautions: Do not deflect the introducer while the basket is within the deflectable portion of the introducer, as this can cause damage to the introducer deflection mechanism. Do not deflect the Volt™ PFA Catheter, Sensor Enabled™ while the basket is in the introducer, as this can cause damage to the catheter deflection mechanism. The first application of PFA will likely result in a significant reduction of amplitude of PV potentials recorded from the electrodes on the catheter. Do not use this as an immediate indication that no further ablation is necessary. The PFA therapy should be delivered in accordance with the Therapy Delivery Parameters. Advance the catheter slowly through the introducer to minimize the risk of air embolism. Do not attempt to use the device before completely reading and understanding the applicable instructions for use. Inspect the package prior to use. Do not use if the packaging or catheter appears damaged. Inspect all components before use. Excessive bending or kinking of the catheter may cause damage to the catheter. Be careful not to twist the electrodes with respect to the catheter shaft; twisting may damage the electrode bond and loosen the electrodes. Release the steering (make the catheter straight) prior to pulling back the catheter into the introducer. Deflate the balloon before pulling the catheter back into the introducer. Overinflation of the balloon may cause damage to the device. Always straighten the catheter shaft and keep the balloon deflated before insertion or withdrawal. Do not use if the catheter appears damaged, kinked, or if there is difficulty in deflecting the distal section to achieve the desired curve. Do not use if the catheter does not hold its curve or if there is difficulty deflecting the catheter. Do not use if there is difficulty inflating or deflating the balloon. Do not use excessive force to advance or withdraw the catheter while inside the introducer when resistance is encountered to avoid potential damage to the catheter. Do not expose catheter to organic solvents such as alcohol. Catheter advancement must be performed with support from visualization modalities such as Intracardiac echo, fluoroscopy, and or compatible navigation and visualization systems to minimize the risk of cardiac damage, perforation, or tamponade. If other catheters are used concomitantly with the Volt™ PFA Catheter, Sensor Enabled™, only use other catheters in close proximity when the balloon is inflated, and never in tandem with the catheter in the same pulmonary vein. Never retract the catheter into the introducer when another catheter is in close proximity. Never use a loop catheter concomitantly with the Volt™ PFA Catheter, Sensor Enabled™ within the same atrial chamber. Retract the catheter into the introducer before using a loop catheter within the same chamber. Prior to therapy delivery, ensure that the guidewire is not touching the basket electrodes to prevent ineffective therapy. Compliance with intended therapy delivery parameters reduces the potential for hemolysis and acute kidney injury. Ensure that vacuum pressure is relieved and balloon is fully deflated. After deflating the balloon, leave the stopcock open between the syringe and the inflation lumen to prevent catheter damage during catheter withdrawal. It is recommended to withdraw the guidewire into the introducer prior to balloon deflation to avoid potential entanglement with spline electrodes. Ensure even spacing for splines and full balloon inflation to reduce potential for generator fault detection. Ensure connection to center lumen stopcock when attempting to inject contrast. The balloon inflation lumen has a blue/grey striped sleeve to visually distinguish it from the center lumen stopcock. Do not touch the guidewire during therapy delivery. Risk of electric shock to the user is possible under rare circumstances in which the guidewire is in contact with an active therapy electrode(s) and the user. During treatment with the catheter, ensure there is no possibility of contact with electrodes from another catheter. To avoid thromboemboli, intravenous heparin should be used when entering the left heart during ablation. Consult the HRS consensus guidelines for anticoagulation strategies pre-, during, and post-catheter ablation. Individual patient anatomy and physician technique may require procedural variations. Maintain an activated clotting time (ACT) of greater than 300 seconds at all times during use of the catheter. Store in a dry place.  After use, the device accessories and packaging should be appropriately classified for disposal, e.g. biohazard, sharps, non-hazardous waste etc., and carefully disposed of in compliance with facility procedures and applicable laws and regulations. Catheter materials are not compatible with magnetic resonance imaging (MRI). Potential Adverse Events: The potential adverse events may be related to the ablation catheter(s) and/or the interventional procedure. The severity and/or the frequency of these potential adverse events may vary and may result in prolonged procedure time and/or additional medical and/or surgical intervention, implantation of a permanent device such as a pacemaker, and in rare cases, may result in death. The following adverse events have been documented for catheter ablation procedures: ▪ Abnormal vision ▪ Acute kidney injury ▪ Air embolism ▪ Anesthesia reaction ▪ Angina/chest pain/discomfort ▪ Aorto-right atrial fistula ▪ Arrhythmias, including exacerbation of preexisting atrial fibrillation ▪ Arteriovenous fistula ▪ AV/SA node stunning (asystole) ▪ Bleeding, including major bleeding requiring surgery or transfusion/hematomas/anemia ▪ Cardiac perforation/tamponade ▪ Cardiac embolism ▪ Cardiovascular injury, including atrial trauma and coronary artery/pulmonary vein trauma ▪ COPD exacerbation ▪ Component damage to Implantable Cardioverter Defibrillator(ICD) or implantable pacemaker ▪ Coronary artery spasm ▪ Cytotoxicity/systemic toxicity/sensitization/endotoxin/pyrogen ▪ Death ▪ Dislodgement of ICD or pacing leads ▪ Electrical shock ▪ Endocarditis ▪ Esophageal lesion ▪ Fever ▪ Foreign body embolism ▪ Heart block/unintended ablation ▪ Heart failure ▪ Hemothorax ▪ Hypotension ▪ Infectious pericarditis ▪ Left atrial esophageal fistula ▪ Myocardial infarction ▪ Neck/back/groin/chest pain/discomfort (general chest pain not associated with MI) ▪ Palpitations ▪ Pericarditis ▪ Pericardial effusion ▪ Phrenic nerve injury ▪ Peripheral vascular dissection/laceration ▪ Pleural effusion ▪ Pneumonia ▪ Pneumothorax ▪ Pseudoaneurysm ▪ Pulmonary edema ▪ Pulmonary embolism ▪ Pulmonary hypertension ▪ Pulmonary vein stenosis ▪ Radiation injury ▪ Respiratory failure/distress/depression/hypoxia ▪ Silent cerebral event/lesion ▪ Stiff Left Atrial Syndrome ▪ Stroke/cerebrovascular accident ▪ Syncope/vasovagal reaction/dizziness ▪ Transient ischemic attack (TIA) ▪ Thromboembolism ▪ Thrombosis/thrombus ▪ Vagal nerve injury including Gastroparesis ▪ Valvular damage or insufficiency

 

Indications: The EnSite™ X EP System is a suggested diagnostic tool in patients for whom electrophysiology studies have been indicated. The EnSite™ X EP System provides information about the electrical activity of the heart and displays catheter location during conventional electrophysiological (EP) procedures. Warnings: For patient safety, any connections that directly connect the patient to the EnSite™ X EP System must be routed through the appropriate modules: EnSite™ X EP System SurfaceLink Module, EnSite™ X EP System 20 pin Catheter Input Module, EnSite™ X EP System 80-pin Catheter Input Module and Direct Connect Ports on the EnSite™ X EP System Amplifier. When using the EnSite™ X EP System, full protection against the effects of cardiac defibrillator discharge and other leakage currents is dependent upon the use of appropriate cables. Refer to the ablation catheter IFU for a listing of adverse events related to the use of this device in conjunction with ablation, as a part of the diagnosis and treatment of cardiac arrhythmias. Non-SE catheters cannot collect location data and should not be used for navigation in VoXel Mode because they do not have a magnetic sensor. However, they can be visualized and display intracardiac signals. Only connect items that have been specified as part of the EnSite X EP System or compatible with the EnSite X EP System to the multiple socket-outlets. The EnSite™ X EP System model display should be used in conjunction with conventional EP techniques to confirm catheter location. The AutoMark feature does not indicate lesion effectiveness. AutoMarks are placed based on user-defined parameters for catheter stability and RF metrics only. PFA AutoMarks are placed based on electrode location and user-defined PFA metrics only. Sudden impedance changes of the body or catheter electrodes caused by the connection of other devices (e.g., stimulator, defibrillator, and other devices) may create a location shift. The 2D and 3D LivePoint Displays should not be used as the primary / sole display of tissue proximity during an Electrophysiology study. Refer to the Current PFA Generator IFU for warnings related to the Volt ™ LivePoint Display. Precautions: Ensure that surface electrodes, Patient Reference Sensors, and associated connectors do not contact one another, electrical ground, or metallic objects. Do not operate the EnSite™ X EP System Field Frame within 10 m of another operating Field Frame. Do not place the EnSite™ X EP System Field Frame Cable inside the measurement volume or wrap it around the EnSite™ X EP System Field Frame, as it may create a magnetic interference. Metallic equipment used in close proximity to the magnetic field during the procedure, such as a sterile drape holder, may cause metal distortion. Do not place tool cables within 30 mm of the EnSite™ X EP System Field Frame Cable. If placed this close-particularly if the cables are parallel to each other the tool cable may become subject to electromagnetic interference. Do not use the EnSite™ X EP System for magnetic catheter localization or magnetic data collection (NavX SE or EnSite VoXel point collection) if other magnetic fields are present.

 

Indications: The Agilis™ NxT Steerable Introducer Dual-Reach™ is indicated for the introduction of various cardiovascular catheters into the heart, including the left side of the heart, during the treatment of cardiac arrhythmias. Contraindications: The Agilis™ NxT Steerable Introducer Dual-Reach™ is contraindicated for: Previous interatrial septal patch. Known or suspected atrial myxoma. Acute myocardial infarction. Unstable angina. Recent cerebral vascular accident (CVA). Patients who do not tolerate anticoagulation therapy. Patients with an active infection. Presence of an intracardiac thrombus. Warnings: Do not alter this device in any way. This device must be used by board-certified electrophysiologists, or EP fellows in training, in a fully-equipped operational EP laboratory. This device is intended for one time use only; do not reprocess or reuse it. Note the product “Use by” date on the package. Any attempt to resterilize and reuse this system may compromise its integrity. Adverse effects of using nonsterile components may include, but are not limited to: Local or systemic infection or reaction, Mechanical damage, Inaccurate functionality. Always aspirate, insert and withdraw components, and exchange catheters slowly to minimize the risk of air emboli. Aspirate all air before fluid infusion from the sideport. Provide continuous heparinized saline infusion while the introducer remains in the vessel. Fibrin may accumulate in or on the introducer tip during the procedure. To prevent dislodgement of potential thrombus, aspirate when removing dilator or catheter. Before removing the steerable introducer, reinsert the guidewire through the introducer, reintroduce the dilator over the guidewire, straighten the steerable introducer, then remove the dilator, guidewire, and introducer as a unit. Maximum in-vivo time: 7 hours. Read the IFU carefully before using this device to help reduce the potential risks and complications associated with the transseptal technique, such as air emboli and perforation of the aorta and left atrium. Aspirate and saline flush the introducer frequently to minimize the potential for thrombus formation. Do not use the introducer without a catheter or dilator supporting the lumen. Use of the introducer directly over a wire without a catheter or dilator supporting the lumen may result in complications that can cause death. For both patients and laboratory staff, cardiac catheterization procedures present the potential for significant x-ray exposure, which can result in acute radiation injury as well as increased risk for somatic and genetic effects due to the x-ray beam intensity and duration of the fluoroscopic imaging. Carefully consider the use of this introducer in pregnant women. Persons with known history of allergies to any of the materials listed below may suffer an allergic reaction to this device. Before use, counsel the patient on the materials contained in the device and discuss a thorough history of allergies. This device contains: Polyether block amide (PEBAX), Polytetrafluoroethylene, ABS, Silicone rubber, DOW Corning 360 fluid , HDPE, MDX/hexane solution, Nylon. Precautions: Federal law (U.S.) restricts this device to sale by or on the order of a physician. Only use this device with equipment that complies with international safety standards. Store in a cool, dark, dry place. Inspect all components before use. Do not use if the packaging or items in the kit appear to be damaged or defective. Conditions requiring special consideration when using this product may be, but are not limited to, small left atrium, marked right atrial enlargement, and marked distortion of the thorax configuration (example, kyphosis or scoliosis). Individual patient anatomy and physician technique may require procedural variations. Potential Adverse Events: The following potential complications may occur during the use of this device, but are not limited to: Arrhythmia. Bleeding Major: bleeding requiring surgery or transfusion, Hematomas or Anemia. Cardiac perforation: Cardiac tamponade, Pericardial complications, Pericardial effusion Hemopericardium, Pneumopericardium, Pericarditis. Cardiovascular injury: Atrial/ventricular trauma, Great vessel perforation, Valvular damage. Cerebral injury: Asymptomatic cerebral emboli (ACE), Stroke/cerebrovascular accident, Transient ischemic attack (TIA). Coronary artery injury. Embolism: Air embolism, Foreign body embolism, Pulmonary embolism, Thromboembolism, Thrombosis/thrombus. Hypotension: Vasovagal reaction. Immunological reaction: Anesthesia reaction, Anaphylaxis. Infection: Endocarditis, Pneumonia, Sepsis/shock. Organ injury: Esophageal injury, Pleural effusion. Pain: Groin. Peripheral vascular injury: Arteriovenous fistula, Dissection, Laceration, Pseudoaneurysm. Superficial tissue injury. Please consult the respective manufacturer's labeling for adverse events associated with the use of either cardiovascular catheters or endomyocardial biopsy devices.

 

Indications for Use: The Current™ PFA Generator is indicated for use with compatible ablation catheters for the treatment of cardiac arrhythmias. Contraindications: There are no known contraindications specific to the use of the Current™ PFA Generator itself. However, users should read and understand the specific indications, contraindications, warnings, and precautions included with any cardiac ablation catheter used in conjunction with the Current™ PFA Generator. Warnings: Misuse of this device may result in serious complications. This device must be used by, or under the supervision of, physicians trained in the techniques of percutaneous electrophysiology studies. For both patients and laboratory staff, cardiac catheterization procedures present the potential for significant X‑ray exposure, which can result in acute radiation injury as well as increased risk for somatic and genetic effects due to the X‑ray beam intensity and duration of the fluoroscopic imaging. Carefully consider the use of this device in pregnant women. The safety and effectiveness of the device is not established in pregnant women or prepubescent children. Carefully consider the use of this device in pregnant women or prepubescent children. Pacemakers and implantable cardioverter/defibrillators can be affected adversely by PFA signals. It is important to: Have temporary external sources of pacing and defibrillation available during ablation. Deactivate ICDs because they can discharge and injure the patient or even damage the ICDs during the ablation procedure. Exercise extreme caution while ablating near atrial or ventricular permanent pacing leads. Perform complete pacing system analysis on all patients after ablation. Ablation within and near the coronary arterial vasculature is associated with myocardial infarction and death. The long-term risk of lesions created by PFA is not established.  When using an EP recording system, the equipment must be front-end isolated or have an isolated patient cable and comply with the IEC 60601‑1 safety requirements for medical electrical systems. Failure of the Current™ PFA Generator can result in an unintended power output increase or the inability to remove power when commanded. In case of system malfunction, attempt to stop PFA delivery by pressing the Standby button on the front panel or turning off the power switch on the rear panel. If those attempts do not turn off the power, disconnect the power cord. Failure to do so can result in operator or patient harm. The Current™ PFA Generator is not suitable for use within Oxygen Rich Environments or in the presence of flammable gasses, including flammable anesthetic mixtures with air, oxygen, or nitrous oxide. Avoid using this equipment adjacent to or stacked with other equipment because it can result in improper operation. If such use is necessary, observe all equipment involved to verify that they are operating normally. To avoid the risk of electric shock, only connect this equipment to a mains power supply with protective earth. Use of accessories, transducers, and cables other than those specified can result in improper operation due to increased electromagnetic emissions or decreased electromagnetic immunity of this equipment. Do not use portable RF communications equipment (including peripherals, such as antenna cables and external antennas) closer than 30 cm (12 in.) to any part of the Current™ PFA Generator (including cables specified by the manufacturer) because it can result in degradation of the equipment. During treatment, ensure there is no possibility of contact with electrodes from another catheter. Do not open the Current™ PFA Generator in attempt to access its internal components. Opening the device may result in personal injury and damage to the generator. Do not position the Current™ PFA Generator so that it is difficult to disconnect the equipment from the mains supply. Do not modify the Current™ PFA Generator. Precautions: Federal (USA) law restricts this device to sale by or on order of a physician. Do not attempt to operate the Current™ PFA Generator before reading this IFU thoroughly. Read, understand, and follow the Current™ PFA Generator IFU carefully. For future reference, keep this IFU in a convenient, readily accessible place. During use of the catheter in the left side of the heart, therapeutic anticoagulation needs to be achieved. Anticoagulation treatment must adhere to the ESC/AHA/ACC or any other consensus guidelines to avoid thromboemboli. Do not immerse cable connectors in fluids; electrical performance can be affected adversely.  The Current™ PFA Generator defaults to the nominal waveform unless the user selects the lower waveform. The Current™ PFA Generator is capable of delivering high voltage. Improper handling of the catheter can result in patient or operator injury, particularly when operating the device. During high voltage delivery, do not allow the patient to contact grounded metal surfaces. Place a non-conductive material between the patient and grounded metal surfaces. Electrode attachments are to be as close to the operating field as possible. Place connecting cables so contact with the patient or other leads is avoided. Advance the catheter with support from visualization modalities such as intracardiac echo (ICE), fluoroscopy, and compatible navigation and visualization systems to minimize the risk of cardiac damage, perforation, or tamponade. Accessory equipment connected to the analog and digital interfaces must comply with the respective IEC standards (IEC 60950 for data-processing equipment and IEC 60601‑1 for medical equipment). Apparent low voltage output or failure of the equipment to function correctly at normal settings may indicate failure of an electrical lead. Do not increase the voltage before checking for obvious defects or misapplication. Place the unit so the airflow around it is adequate for cooling. Inspect and test reusable cables and accessories regularly. Only connect items that are specified as part of the system.  To reduce the risk of accidental burns, avoid skin to skin contact (for example, between the arms and body of the patient) by inserting dry gauze. Place monitoring electrodes as far as possible from surgical electrodes when surgical equipment and physiological monitoring equipment are used simultaneously. This equipment generates, uses, and can radiate energy. If not installed and used in accordance with the instructions, this equipment may be interfered with by, or cause harmful interference to, other equipment in the vicinity, even if the other equipment complies with CISPR emission requirements. However, there is no guarantee that interference will not occur in a particular installation. If this equipment does cause harmful interference to devices, which can be determined by turning the equipment off and on, the user is encouraged to correct the interference by one or more of the following measures: Reorient or relocate the receiving device. Increase separation between the equipment. Connect the equipment into an outlet on a circuit different from that to which the other device(s) are connected. Consult the manufacturer for help. Follow the system installation to achieve optimal use. In the event of an error or warning message, check the programmed ablation parameters against the specific ablation catheter IFU before continuing delivery of ablation energy to the patient. To ensure electrical safety, do not use the USB ports to connect this device to other non‑Abbott Medical powered devices. When using non‑Abbott Medical devices, the USB ports should only be used with port powered devices such as a USB flash drive, keyboard, or mouse. The USB ports are not electrically isolated. Do not touch the USB port and the patient simultaneously. To ensure electrical safety, do not touch the HDMI ports and the patient simultaneously; the HDMI ports are not electrically isolated. External monitors/ switches/hubs that are non‑Abbott Medical devices must be IEC 62368 compliant. If the system is used with an uninterruptible power supply, this device should not be connected to an external monitor. The user is responsible for compliance with IEC 60601‑1 safety requirements for medical electrical systems and IEC 60601‑1 Edition 3.1, Clause 16 when connecting this device to other devices. Monitoring systems incorporating high-frequency current-limiting devices are recommended.  Studies have shown that smoke generated during electrocautery procedures can be potentially harmful to patients and the surgical team. These studies recommend adequately ventilating the smoke by using a surgical-smoke evacuator or other means. Do not operate or position the Current™ PFA Generator and its accessories within the vicinity of magnetic resonance imaging (MRI) equipment. The Current™ PFA Generator and its accessories have not been evaluated for safety, functionality, or compatibility within the MRI environment. Interaction with MRI equipment may adversely impact the Current™ PFA Generator's performance, degrade MRI quality, and result in patient harm. Do not clean the electrical contacts/pins of the connectors. Do not clean system components with bleach. Do not apply cleaners while the system is warm to the touch. Do not sterilize system components. Do not immerse system components in liquid. Turn off and disconnect power to the Current™ PFA Generator before cleaning it. Do not autoclave any Current™ PFA Generator component. Autoclaving may damage the system components. Dispose of/recycle packaging materials according to any applicable facility procedures and local regulations. At the end of useful life, classify the hardware for disposal/recycle (example: electrical equipment, non-hazardous waste, and so forth) and dispose of/recycle the hardware according to any applicable facility procedures and local regulations. The IFU is recyclable. Potential Adverse Events: The potential adverse events may be related to the ablation catheter(s) and/or the interventional procedure. The severity and/or the frequency of these potential adverse events may vary and may result in prolonged procedure time and/or additional medical and/or surgical intervention, implantation of a permanent device such as a pacemaker, and in rare cases, may result in death. The following adverse events have been documented for catheter ablation procedures: ▪ Abnormal vision ▪ Acute kidney injury ▪ Air embolism ▪ Anesthesia reaction ▪ Angina/chest pain/discomfort ▪ Aorto-right atrial fistula ▪ Arrhythmias, including exacerbation of preexisting atrial fibrillation ▪ Arteriovenous fistula ▪ AV/SA node stunning (asystole) ▪Bleeding, including major bleeding requiring surgery or transfusion/hematomas/anemia ▪ Cardiac perforation/tamponade ▪Cardiac embolism ▪ Cardiovascular injury, including atrial trauma and coronary artery/pulmonary vein trauma ▪ COPD exacerbation ▪ Component damage to Implantable Cardioverter Defibrillator(ICD) or implantable pacemaker ▪ Coronary artery spasm ▪ Cytotoxicity/systemic toxicity/sensitization/endotoxin/pyrogen ▪ Death ▪ Dislodgement of ICD or pacing leads ▪ Electrical shock ▪ Endocarditis ▪ Esophageal lesion ▪ Fever ▪ Foreign body embolism ▪ Heart block/unintended ablation ▪ Heart failure ▪ Hemothorax ▪ Hypotension ▪ Infectious pericarditis ▪ Left atrial esophageal fistula ▪ Myocardial infarction ▪ Neck/back/groin/chest pain/discomfort (general chest pain not associated with MI) ▪ Palpitations ▪Pericarditis ▪ Pericardial effusion ▪ Phrenic nerve injury ▪ Peripheral vascular dissection/laceration ▪ Pleural effusion ▪Pneumonia ▪ Pneumothorax ▪ Pseudoaneurysm ▪ Pulmonary edema ▪ Pulmonary embolism ▪ Pulmonary hypertension ▪Pulmonary vein stenosis ▪ Radiation injury ▪ Respiratory failure/distress/depression/hypoxia ▪ Silent cerebral event/lesion ▪ Stiff Left Atrial Syndrome ▪ Stroke/cerebrovascular accident ▪ Syncope/vasovagal reaction/dizziness ▪Transient ischemic attack (TIA) ▪ Thromboembolism ▪ Thrombosis/thrombus ▪ Vagal nerve injury including Gastroparesis ▪ Valvular damage or insufficiency

Amplatzer™ Amulet™ Left Atrial Appendage Occluder

INDICATION FOR USE

The Amplatzer™ Amulet™ Left Atrial Appendage Occluder is a percutaneous transcatheter device intended to reduce the risk of thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular atrial fibrillation and who are at increased risk for stroke and systemic embolism based on CHADS2 or CHA2DS2-VASc scores, are suitable for short term anticoagulation therapy, and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation, taking into consideration the safety and effectiveness of the device.

CONTRAINDICATIONS

The Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is contraindicated for patients:

  • With the presence of intracardiac thrombus.
  • With active endocarditis or other infections producing bacteremia.
  • Where placement of the device would interfere with any intracardiac or intravascular structures.

POTENTIAL ADVERSE EVENTS

Potential adverse events associated with the device or implant procedure include, but are not limited to, the following: Air embolism; Airway trauma; Allergic reaction; Anemia; Anesthesia reaction (nausea, vasovagal reaction, confusion/altered mental status or other); Arrhythmia; Atrial septal defect; Bleeding; Cardiac arrest; Cardiac tamponade; Chest pain/discomfort; Congestive heart failure; Death; Device embolization; Device erosion; Device malfunction; Device malposition; Device migration; Device-related thrombus; Fever; Hematuria; Hypertension/hypotension; Infection; Multi-organ failure; Myocardial infarction; Perforation; Pericardial effusion; Pleural effusion; Renal failure/dysfunction; Respiratory failure; Seizure; Significant residual flow; Stroke; Thrombocytopenia; Thromboembolism: peripheral and pulmonary; Thrombus formation; Transient ischemic attack; Valvular regurgitation/insufficiency; Vascular access site injury (hematoma, pseudoaneurysm, arteriovenous fistula, groin pain or other); Vessel trauma/injury.

FreeStyle Libre 3 System

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

GET INFORMED

  • Before using the App, please review the complete product instructions and safety information in the User's Manual and take a look at the Interactive Tutorial on our website www.FreeStyleLibre.com. Tips for Kids are there too if you need.
  • Be safe and follow the instructions properly. Using the System incorrectly could cause you to miss a severe low or high glucose event and/or make a harmful treatment decision.
  • You'll always find the latest version of the User's Manual, including performance data in the Support section at www.FreeStyleLibre.com. If you need a free printed copy, just call Customer Service: 1-855-632-8658, 7 days a week from 8 a.m. to 8 p.m. Eastern Time; excluding holidays.
  • Talk to your health care professional about how to use your Sensor glucose information to help manage your diabetes.
  • During the first 12 hours of Sensor wear the symbol will display, and you cannot use Sensor values to make treatment decisions during this time. Confirm Sensor glucose readings with a blood glucose test before making treatment decisions during the first 12 hours of Sensor wear when you see the symbol.

COMPATIBLE SENSORS

You can use Libre app with the FreeStyle Libre 3 Sensor and the FreeStyle Libre 3 Plus Sensor (simply referred to as Libre 3 Sensor and Libre 3 Plus Sensor). Some of the information in the User's Manual and the performance characteristics vary between the Sensors. Please reference the labeling content that applies to your Sensor. Make sure you have a Libre 3 Plus Sensor if you plan to connect with a compatible automated insulin dosing (AID) system.

Libre 3 Sensor

  • 14 day wear
  • Can be used by people age 4 and older
  • Do not use with automated insulin dosing (AID) systems
  • Taking more than 500 mg of Vitamin C per day may affect Sensor readings. This could cause you to miss a severe low glucose event.

Libre 3 Plus Sensor

  • 15 day wear
  • Can be used by people age 2 and older
  • Can be used with compatible automated insulin dosing (AID) systems
  • Taking more than 1000 mg of Vitamin C per day may falsely raise Sensor readings. This could cause you to miss a severe low glucose event. You can take up to 1000 mg of Vitamin C per day and still use the Sensor readings to make treatment decisions.

INDICATION FOR USE

Libre 3 Sensor users:

The FreeStyle Libre 3 Continuous Glucose Monitoring System is a real time continuous glucose monitoring (CGM) device with alarms capability indicated for the management of diabetes in persons age 4 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated.

The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time.

The System is also intended to autonomously communicate with digitally connected devices. The System can be used alone or in conjunction with these digitally connected devices where the user manually controls actions for therapy decisions.

Libre 3 Plus Sensor users:

The FreeStyle Libre 3 Continuous Glucose Monitoring System is a real time continuous glucose monitoring (CGM) device with alarms capability indicated for the management of diabetes in persons age 2 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated.

The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time.

The System is also intended to autonomously communicate with digitally connected devices, including automated insulin dosing (AID) systems. The System can be used alone or in conjunction with these digitally connected devices for the purpose of managing diabetes.

CHECK COMPATIBILITY

  • Libre app is only compatible with certain phones and operating systems. Always check the Phone and OS Compatibility Guide before upgrading your phone or its operating system. This Guide is available in the App's Help Menu and in the Support section on www.FreeStyleLibre.com.
  • Authorized compatible products that you can use with your Sensor are also listed at www.FreeStyleLibre.com. Using your Sensor with products that are not on this list may cause inaccurate glucose readings. If you use a computer, you are responsible for keeping it secure and up to date, for example by using anti-virus software and installing system updates.

CONTRAINDICATIONS

Diathermy: Remove all parts of your System before high-frequency electrical heat (diathermy) treatment. The effect of diathermy on the System hasn’t been tested. The exposure may damage the Sensor, which could impact proper device function and cause inaccurate readings.

Automated Insulin Dosing (AID): The Libre 3 Sensor must not be used with AID systems, including closed loop and insulin suspend systems.

WARNINGS

  • Don't ignore low or high glucose symptoms. Use your blood glucose meter to make treatment decisions when your Sensor readings don’t match your symptoms or expectations. Get medical attention when appropriate.
  • Use your blood glucose meter to make treatment decisions when your Sensor reading doesn’t match how you feel, has no number, or you see the symbol during the first 12 hours of Sensor wear. You cannot use Sensor values to make treatment decisions during the first 12 hours.
  • Choking hazard: The System has small parts that may be dangerous if swallowed.
  • You must have access to a blood glucose monitoring system. One is not provided when you use the App.

CAUTIONS – OVERALL SYSTEM

What to know before using the System:

  • Avoid infection by taking standard precautions for bloodborne pathogens.
  • Don't share the App with another person to avoid confusing glucose information.
  • The App doesn’t share data with your System’s Reader. Before you start a Sensor, you must choose whether to use the Reader or the App with the Sensor. Once you start a Sensor, you cannot switch your device.
  • Make sure that your phone and Sensor Kits are kept in a safe place and under your control. This is important to help stop anyone from accessing or tampering with the System.

Who should not use the System:

  • Don't use in people under the age in the Indications for Use. The System is not cleared for use under this age.
  • Don't use if you are on dialysis or critically ill. The System hasn’t been evaluated in these groups. Sensor readings may be inaccurate.
  • The System hasn’t been evaluated when used with other implanted medical devices, such as pacemakers.

When is Sensor glucose different from blood glucose:

  • Glucose levels in interstitial fluid (what your Sensor measures) can be different from blood glucose levels (what your meter measures). You may notice this when your glucose is changing quickly. For example, after eating, taking insulin, or exercising.

CAUTIONS – APP USE

What to know about the App:

  • Disable your phone’s automatic operating system (OS) updates. Before updating your phone’s OS or the App, check the Phone and OS Compatibility Guide to see if the App is compatible. This Guide is available in the App’s Help menu and also in the Support section on www.FreeStyleLibre.com. Check it regularly to make sure that your phone and OS remain compatible with the App.
  • We may contact you if an App or OS update will make your previously compatible phone incompatible. Make sure that your LibreView account has your current email address to receive important information.
  • After an OS update, open the App and check your device settings to make sure it's working properly. Some OS features may impact your ability to get alarms or glucose readings. For example, if you use the iPhone Screen Time feature, add Libre app to the list of Always Allowed apps to ensure that you receive alarms. Or, if you use an Android phone, don’t use the Android Digital Wellbeing app.
  • If you restart your phone, open the App to make sure it’s working properly.
  • During set up, the App asks for phone permissions. Please allow these. If your phone is not set up properly, you will not be able to use the App and will not get alarms, including the Urgent Low Glucose Alarm. Confirm your settings are as follows:
    • iPhone settings:
      • In the phone settings, keep Bluetooth ON
      • In the phone settings for the App, allow the App to access Bluetooth
      • In the phone settings for the App under Notifications, keep Critical Alerts ON
    • Android phone settings:
      • In the phone settings, keep Bluetooth ON
      • In the phone settings for the App, keep Do Not Disturb access permission ON
      • In the phone settings for the App, keep Nearby Devices permission ON (for Android 12 and above)

Follow the instructions in the App to turn on these settings and permissions. If your phone is not configured correctly, you will see Alarms Unavailable on your screen. 

  • Android users may need to add Libre app to the list of the apps that will not be restricted or put to sleep.
  • If you adjust the phone ringer volume (iPhone) or Media volume (Android) to silent or use the phone do not disturb setting, keep 'Override Do Not Disturb' setting in the App ON for Low Glucose, High Glucose, and Signal Loss Alarms to ensure you receive audible alarms.

For you to receive alarms:

  • Keep your phone charged and turned on.
  • Don't force close the App. The App must be running in the background to get alarms.
  • Always keep your phone within 33 feet of you, with no obstacles between you. The Sensor itself will not issue alarms! If you’re out of range, you may not get alarms. If you want to use the App's optional alarms, keep these turned on.
  • Disconnect headphones or speakers from your phone when not in use. You may miss alarm sounds if you don’t.
  • Remember that if you have accessories connected to your phone (like wireless headphones or a smartwatch), you may get alarms on only one device, not all.

Go to the Alarms section in the user manual to learn more about the App's alarms.

CAUTIONS – SENSOR USE

What to know before you apply the Sensor:

  • The Sensor inserts just under your skin. You may have some bruising or bleeding.
  • Clean your hands before handling the Sensor Kit contents. This will help prevent infection.
  • Carefully follow the instructions to prepare the application site on the back of your upper arm. This will help your Sensor stay on for the full wear time and not fall off early. Wash the site using a plain soap. Then, dry and clean with an alcohol wipe. This removes any oily residue and helps the Sensor stick. Allow the site to air dry before applying the Sensor.
  • Only apply the Sensor to the back of your upper arm. The Sensor may not work properly in other areas. Avoid scars, moles, stretch marks, and lumps. Choose an area that stays mostly flat (no bending or folding) during your day. Keep at least 1 inch away from insulin injection sites.
  • Change sites between Sensors so your skin can recover.

What to know about wearing a Sensor:

  • Your Sensor's product insert tells you how long you can wear your Sensor. Remember to always have your next Sensor on hand before your current one ends so you can keep getting your glucose readings.
  • If your Sensor stops working and you don’t have another Sensor, use another method to check your glucose and make treatment decisions.
  • The App can detect when the Sensor isn’t working properly. It will shut your Sensor off and tell you to replace it. This may happen if the Sensor gets knocked off your body, or if there’s a problem with it. Call us if you receive a Replace Sensor message before the end of your wear time. Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays.
  • Some people may be sensitive to the adhesive that keeps the Sensor attached to the skin. If you notice significant skin irritation around or under your Sensor, remove the Sensor. Contact your health care professional before continuing to use the System.
  • Intense exercise may cause your Sensor to loosen due to sweat or Sensor movement. If the Sensor gets loose or its tip comes out of your skin, you may get no readings or unreliable low readings. Remove your Sensor and apply a new one.
  • Don’t attempt to reinsert the old one! Call us if any Sensor gets loose or falls off before the end of your wear time. Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays. Don't reuse Sensors. The Sensor and Sensor Applicator are designed for single use. Reuse may result in no glucose readings and infection. Not suitable for re-sterilization. Further exposure to irradiation may cause unreliable low results.
  • If a Sensor breaks in your body, call your health care professional.

How to store the Sensor Kit:

  • Store between 36°F and 82°F. Storing outside this range may cause inaccurate Sensor glucose readings.
  • If you think that the temperature may exceed 82°F (for example, in an un-airconditioned home in summer), you should refrigerate your Sensor Kit. Don’t freeze your Sensor Kit.
  • Store in a cool, dry place. Don’t store in a parked car on a hot day.
  • Store between 10-90% non-condensing humidity.

When to remove the Sensor:

  • If the Sensor is becoming loose or if its tip is coming out of your skin, you may get no readings. Or, you may get unreliable readings that don’t match how you feel. Check to make sure your Sensor is not loose. If it’s loose, remove it and apply a new one. Please call Customer Service.
  • If you think your glucose readings are incorrect or don’t match how you feel, do a blood glucose test on your finger to check your glucose. If the problem continues, remove the Sensor and apply a new one. Call Customer Service: 1-855-632-8658. Available 7 days a week, 8 a.m. to 8 p.m. Eastern Time; excluding holidays.

When not to use the Sensor:

  • Don't use if the Sensor Kit carton or Sensor Applicator look damaged or if tamper label indicates Sensor Applicator has already been opened. Infection may result.
  • Don't use if Sensor Kit contents have expired.

Go to the Applying Your Sensor section in the user manual to learn how to prepare and apply your Sensor.

MRI safety information:

  • You can safely have a 1.5T or 3T MRI exam while wearing your Sensor, under the conditions listed below. Injury may result if the conditions are not followed. Leave your phone and Reader outside of the exam room. Sensor readings may be inaccurate during the MRI, but System function returns fully back to normal after 1 hour.

Parameter

Condition

Device Name

Libre 3 or Libre 3 Plus Sensor

Static Magnetic Field Strength (B0)

1.5T and 3T

MR Scanner Type

Cylindrical

B0 Field Orientation

Horizontal

Maximum Spatial Field Gradient

40 T/m (4,000 G/cm)

Maximum Gradient Slew Rate

200 T/m/s per axis

RF Excitation

Circularly Polarized (CP)

RF Transmit Coil Type

Integrated Whole Body Transmit Coil

Operating Mode

Normal Operating Mode

RF Conditions

Maximum Whole-body SAR: 2 W/kg

Scan Duration

1.5T scanners: Up to 1 hour of continuous scanning without cooling period.

_________________________________________________________________________________

3T scanners: Up to 12 minutes of scanning between the pelvis and the sternum with a cooling period of 2 minutes between scans. Up to 1 hour of continuous scanning without cooling period when scanning elsewhere.

Scan Regions

All landmark locations are acceptable within the region-specific scan durations described above.

Image Artifact

The presence of a Libre 3 or Libre 3 Plus Sensor may produce an image artifact of 5.8 cm. Some manipulation of scan parameters may be needed to compensate for the artifact.

Device Functionality

Device readings may be inaccurate during active MRI scanning but device functionality fully returns to normal operation by 1 hour following MRI exposure.

SECURITY INFORMATION

  • You are responsible for properly securing and managing your phone. If you suspect an adverse cybersecurity event related to the App, contact Customer Service.
  • The App is not intended for use on a phone that has been altered or customized to remove, replace or circumvent the manufacturer’s approved configuration or use restriction, or that otherwise violates the manufacturer’s warranty.
  • Don't use the App on a jailbroken or rooted device. When used on a jailbroken or rooted device or in the case of a potential cybersecurity event, the App will stop without notification. This means you won't receive alarms and will need to use another method to check your glucose. Please contact Customer Service.
  • Use of an unsupported mobile device or OS version may affect App security and functionality. You are responsible for the risks associated with the use of the App on an unsupported mobile device or OS version.
  • The App should only be downloaded and/or updated through authorized distributors, including the App Store (iPhone) and Google Play Store (Android).

INTERFERING SUBSTANCES

Libre 3 Sensor

Taking Vitamin C supplements while wearing the Sensor may falsely raise Sensor glucose readings. Taking more than 500 mg of Vitamin C per day may affect the Sensor readings. This could cause you to miss a severe low glucose event. Vitamin C can be found in supplements including multivitamins. Some supplements, including cold remedies such as Airborne® and Emergen-C®, may contain high doses of 1000 mg of Vitamin C. These should not be taken while using the Sensor. See your health care professional to understand how long Vitamin C is active in your body.

Libre 3 Plus Sensor

Taking more than 1000 mg of Vitamin C per day may falsely raise your Sensor readings. This could cause you to miss a severe low glucose event. Vitamin C can be found in supplements including multivitamins and cold remedies such as Airborne® and Emergen-C®. See your health care professional to understand how long Vitamin C is active in your body.

Cologuard

Important Risk Information

Indications for Use

The Cologuard® and Cologuard Plus™ tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA)/advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Do not use the Cologuard products if you have:

  • Had adenomas, which are a type of colon polyp that can sometimes become cancer
  • inflammatory bowel disease (IBD) or other hereditary syndromes
  • a personal or first-degree family history of colorectal cancer
  • or a positive result from another colon cancer screening method within that test's recommended screening interval.

Talk to your healthcare provider if any of these situations apply to you.

Cologuard results should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for colonoscopy.

A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their healthcare provider when they need to be tested again.

False positives and false negatives can occur. It is important to talk to your doctor about your test results.

Do not provide a sample if you have diarrhea or have blood in your urine or stool.

The risks related to using the Cologuard collection kit are low, with no serious adverse events reported among people in a clinical trial. You should be careful when opening and closing the lids to avoid the risk of hand strain.

Please read the Instructions for Use and talk to your healthcare provider to see if a Cologuard test is right for you. This product is available by prescription only.

Refer to the Cologuard Patient Brochure or the Cologuard Plus Patient Brochure for additional information on the about the benefits and risk of using each version of the Cologuard product for CRC screening.

TactiFlex Duo, Sensor Enabled

Rx Only. Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use.

United States: Required Safety Information

Indication: TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ is indicated for use in cardiac electrophysiological mapping and ablation for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible radiofrequency (RF) or pulsed field (PF) generator and three-dimensional mapping system. Contraindications: Do not use in patients with active systemic infection, intracardiac thrombus or myxoma, prosthetic heart valves, recent ventriculotomy or atriotomy (<4 weeks), inability to receive adequate anticoagulation, or in patients for whom the specified transseptal or retrograde approaches are contraindicated. Use in the coronary vasculature is contraindicated. Warnings: Application of RF energy on the left atrial posterior wall exceeding 40 W in power, or use of contact force ≥15 g, increases the risk of esophageal perforating complications including atrio-esophageal fistula and death. Application of RF energy outside of the power and duration recommendations may increase the likelihood of steam pop occurrence. The combination of intracoronary placement of the ablation catheter and RF energy application has been associated with myocardial infarction and death. Contact force accuracy above 50 g has not been established. Increased contact force may increase the risk for perforation during manipulation of the catheter. Cases of delayed onset of atrio‑esophageal fistula (AEF) have been reported in association with radiofrequency catheter ablation procedures. While rare, AEF is associated with significant morbidity and mortality. A high index of suspicion for AEF should be maintained in patients who present with symptoms including but not limited to fever, neurological deficits, hematemesis, septic shock, and dysphagia in the several weeks after a left atrial ablation procedure. Inspect tubing, connections, and saline irrigation for air bubbles prior to and throughout its use in the procedure. Air or bubbles in the saline irrigation may cause emboli, potential injury, or fatality. To avoid thromboemboli, intravenous heparin should be used when entering the left heart during ablation. Patients undergoing septal accessory pathway ablation are at risk for complete AV block which requires the implantation of a permanent pacemaker. Permanent pacing may be required in patients who experience inadvertent complete AV block as a result of RF ablation. Implantable pacemakers and implantable cardioverter/defibrillator (ICDs) may be adversely affected by RF or PFA current. It is important to: have temporary external sources of pacing and defibrillation available during ablation, temporarily reprogram the pacing system to minimum output to minimize risk of inappropriate pacing, exercise extreme caution during ablation when in close proximity to atrial or ventricular permanent leads, program the ICD to the OFF mode during the ablation procedure, perform complete implantable device analysis on all patients after ablation. Take precautions to avoid injuring the phrenic nerve, including pacing to identify the proximity of the nerve, and, when using RF, appropriately reducing power. Caution should be taken when placing lesions in the proximity of the specialized conduction system. Collateral anatomical structures need to be considered (e.g. phrenic nerve, coronary arteries and native conduction system) while manipulating catheters and prior to ablation. PF energy should not be applied to the cavotricuspid isthmus. Ablations in areas adjacent to the coronary arteries may lead to coronary artery spasm and/or injury, and the resulting myocardial injury may be fatal. Precautions: Use the catheter only in a fully equipped electrophysiology laboratory. It is recommended that the laboratory should include corresponding equipment including, but not limited to, fluoroscopy, stimulator, recording, defibrillator or ultrasound/intracardiac echocardiography (ICE) units. The PFA therapy should be delivered in accordance with Therapy Delivery Parameters. The first application of PFA will likely result in a significant reduction of amplitude of PV potentials recorded from the electrodes on the catheter. Do not use this as an immediate indication that no further ablation is necessary. During treatment with the catheter, ensure there is no possibility of contact with the electrodes or guidewire from another catheter. Always straighten the catheter tip before insertion or withdrawal. If irrigation flow is interrupted, immediately inspect and re flush the catheter outside of the patient. Re-establish irrigation flow prior to placing catheter in the body. Irrigated ablation systems have been shown to create larger lesions than standard radiofrequency ablation catheters. Be careful when ablating near electrically vulnerable, thin walled, or other arterial structures. Potential Adverse Events: Potential adverse events include, but are not limited to, death, stroke, transient ischemic attack (TIA), atrio-esophageal fistula (AEF)/esophageal injury, phrenic nerve injury/diaphragmatic paralysis, and serious cardiovascular complications including cardiac tamponade, cardiac perforation, myocardial infarction, heart block requiring permanent pacemaker implantation, pulmonary vein stenosis, thromboembolism, and major bleeding or vascular access complications. Refer to the Instructions for Use for a complete list of adverse events.

SimpleScreen™ CRC test

Intended use

The SimpleScreen CRC test is a qualitative, in vitro diagnostic test intended to detect molecular signals associated with colorectal cancer. SimpleScreen CRC utilizes circulating cell-free DNA from plasma of peripheral whole blood collected in the SimpleScreen CRC blood collection kit. SimpleScreen CRC is indicated for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. Patients with a positive result should be followed by colonoscopy. SimpleScreen CRC is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals.

Precaution
Based on data from clinical studies, SimpleScreen CRC has limited detection of Stage I (57%) colorectal cancer (64% when U.S. 2020 Census age-sex adjusted) and does not detect 87% of advanced precancerous lesions (86% when U.S. 2020 Census age-sex adjusted). One out of 10 patients with a negative SimpleScreen CRC result may have a precancer that would have been detected by a screening colonoscopy.

Contraindications and limitations
The SimpleScreen CRC test is not indicated for patients who have the following:

  • A personal history of colorectal cancer (CRC), advanced precancerous lesions (APL), or other related cancers
  • A first-degree family history of colorectal cancer
  • A positive result on another colorectal cancer screening method within that test's recommended screening interval
  • A personal history of a condition associated with high risk for colorectal cancer such as inflammatory bowel disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease, or certain hereditary syndromes.

Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. SimpleScreen CRC may produce a false negative or false positive result. A false negative result may occur when the SimpleScreen CRC test does not detect colorectal cancer or advanced precancerous lesions although a colonoscopy would identify either of these findings. A negative result does not guarantee the absence of colorectal cancer or advanced precancerous lesions, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline recommended intervals. A false positive result may occur when the SimpleScreen CRC test generates a positive result while a colonoscopy will not find colorectal cancer or advanced precancerous lesions.

Refer to the SimpleScreen CRC Patient Information Sheet for additional information about the benefits and risks of using the SimpleScreen CRC test.

Rx only.

AVEIR

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications for Use: The AVEIR™ Leadless Pacemaker system is indicated for management of one or more of the following chronic clinical presentations: syncope, pre-syncope, fatigue, disorientation, and one or more of the indications which follow. Rate-modulated pacing is indicated for patients with chronotropic incompetence, and for those who would benefit from increased stimulation rates concurrent with physical activity. Dual-chamber pacing is indicated for patients exhibiting one or more of the following conditions: sick sinus syndrome; chronic, symptomatic second- and third-degree AV block; recurrent Adams-Stokes syndrome; symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out. Atrial pacing is indicated for patients with sinus node dysfunction and normal AV and intraventricular conduction systems. Ventricular pacing is indicated for patients with significant bradycardia and: normal sinus rhythm with only rare episodes of AV block or sinus arrest, or chronic atrial fibrillation. 

Intended Use: The AVEIR™ Leadless Pacemaker (LP) is designed to provide bradycardia pacing as a pulse generator with built-in battery and electrodes for implantation in the right ventricle and the right atrium. The LP is intended to provide sensing of intrinsic cardiac signals and delivery of cardiac pacing therapy within the implanted chamber for the target treatment group. The LP is also intended to operate optionally with another co-implanted LP to provide dual-chamber pacing therapy.

The AVEIR™ Delivery Catheter is intended to be used in the vasculature and the cardiovascular system to deliver and manipulate an LP. Delivery and manipulation includes implanting an LP within the target chamber of the heart.

Contraindications: Use of the AVEIR™ Leadless Pacemaker is contraindicated in these cases:

  • In patients with an implanted inferior vena cava filter, femoral access is contraindicated.
  • In patients with an implanted superior vena cava filter, internal jugular access is contraindicated.
  • Use is contraindicated in patients with a mechanical tricuspid valve because of interference between this device and the delivery system during implantation.
  • In patients who are known to be hypersensitive to device material components or a single dose of 1.0 milligram of dexamethasone sodium phosphates.

Adverse Events: Potential complications associated with the use of the AVEIR™ Leadless Pacemaker system are the same as with the use of single or dual chamber pacemakers with active fixation pacing leads including, but not limited to: cardiac arrhythmias; Carotid artery injury; Cardiac perforation; Cardiac tamponade; Cerebrovascular accident (CVA); Death; Diaphragmatic/phrenic nerve stimulation/extra-cardiac stimulation; endocarditis; Heart failure; Hypotension; Hypersensitivity reaction to device materials, contrast media, or medications; Infection; Pacemaker syndrome; Palpitations; Pericardial effusion; Pericarditis; Pneumothorax/Hemothorax; RV-pacing induced cardiomyopathy; Syncope; Thoracic/lymphatic duct injury; Valve damage or regurgitation. Adverse device effects include the following: Battery malfunction/premature battery depletion; Corrupted, intermittent, or loss of i2i™ communication; Device dislodgement; Embolization of foreign material; Helix distortion; Inadequate fixation during implant with or without device migration (Intra-procedural); Inability to interrogate or program the LP due to programmer or LP malfunction; Inability to release/re-dock of the LP from catheter; Inappropriate sensor response; Increased capture threshold (Exit block, High-impedance, Threshold elevation); Intermittent or complete loss of capture, pacing or sensing (non-battery related); Interruption of desired LP function due to electrical interference, either electromyogenic or electromagnetic; Mechanical malfunction of the LP (non-battery related); Oversensing; Premature deployment; Undersensing. As with any percutaneous catheterization procedure, potential complications include, but are not limited to: Air embolism; Bleeding or hematoma; General procedural risks and complications from comorbidities, including but not limited to anesthetic complications, dyspnea, respiratory failure, syncope, pneumonia, hypertension, hypotension, cardiac failure, kidney failure due to reaction to contrast media, pain and anemia; Local and systemic infection; Peripheral nerve damage; Thrombus formation; Thromboembolism; Vascular access complications, such as arteriovenous fistula, pseudoaneurysm, perforation, dissection, puncture, venous occlusion.

Refer to the User’s Manual for detailed indications, contraindications, warnings, precautions, and adverse events.

™ Indicates a trademark of the Abbott group of companies. 

‡ Indicates a third-party trademark, which is property of its respective owner.

Loading...